CEFTAZIDIME 1g, 2g, 500mg-EXIR

Vial Ceftazidime 1g, 2g, 500mg ( contains strile powder for injection)

Generic Name of Product Brand Name Dosage Form Strength Pharmacologic Group Therapeutic Group Unit Per Pack
Ceftazidime - Vial 1000/2000/500 Cephalosporin Antibacterial Agent 12

Indications And Usage

1)Lower Respiratory Tract Infections, including pneumonia, caused by Pseudomonas aeruginosa and other Pseudomonas spp.; Haemophilus influenzae, including ampicillin-resistant strains; Klebsiella spp.; Enterobacter spp.; Proteus mirabilis; Escherichia coli; Serratia spp.; Citrobacter spp.; Streptococcus pneumoniae; and Staphylococcus aureus (methicillin-susceptible strains).

2)Skin and Skin-Structure Infections caused by Pseudomonas aeruginosa; Klebsiella spp.; Escherichia coli; Proteus spp., including Proteus mirabilis and indole-positive Proteus; Enterobacter spp.; Serratia spp.; Staphylococcus aureus (methicillin-susceptible strains); and Streptococcus pyogenes (group A beta-hemolytic streptococci).

3)Urinary Tract Infections, both complicated and uncomplicated, caused by Pseudomonas aeruginosa; Enterobacter spp.; Proteus spp., including Proteus mirabilis and indole-positive Proteus; Klebsiella spp.; and Escherichia coli.

4)Bacterial Septicemia caused by Pseudomonas aeruginosa, Klebsiella spp., Haemophilus influenzae, Escherichia coli, Serratia spp., Streptococcus pneumoniae, and Staphylococcus aureus (methicillin-susceptible strains).

5)Bone and Joint Infections caused by Pseudomonas aeruginosa, Klebsiella spp., Enterobacter spp., and Staphylococcus aureus (methicillin-susceptible strains).

6)Gynecologic Infections, including endometritis, pelvic cellulitis, and other infections of the female genital tract caused by Escherichia coli.

7)Intra-abdominal Infections, including peritonitis caused by Escherichia coli, Klebsiella spp., and Staphylococcus aureus (methicillin-susceptible strains) and polymicrobial infections caused by aerobic and anaerobic organisms and Bacteroides spp. (many strains of Bacteroides fragilis are resistant). 8)Central Nervous System Infections, including meningitis, caused by Haemophilus influenzae and Neisseria meningitidis. Ceftazidime has also been used successfully in a limited number of cases of meningitis due to Pseudomonas aeruginosa and Streptococcus pneumoniae.Ceftazidime for injection, may be used alone in cases of confirmed or suspected sepsis. Ceftazidime has been used successfully in clinical trials as empiric therapy in cases where various concomitant therapies with other antibacterial drugs have been used. Ceftazidime for injection, may also be used concomitantly with other antibacterial drugs, such as aminoglycosides, vancomycin, and clindamycin; in severe and life-threatening infections; and in the immunocompromised patient. When such concomitant treatment is appropriate, prescribing information in the labeling for the other antibacterial drugs should be followed. The dose depends on the severity of the infection and the patient's condition.

7)To reduce the development of drug-resistant bacteria and maintain the effectiveness of ceftazidime for injection, and other antibacterial drugs, ceftazidime for injection, should be used only to treat or prevent infections that are proven or strongly suspected to be caused by susceptible bacteria. When culture and susceptibility information are available, they should be considered in selecting or modifying antibacterial therapy. In the absence of such data, local epidemiology and susceptibility patterns may contribute to the empiric selection of therapy.






Usual recommended dosage

1 gram intravenous

every 8 to 12 hours

Uncomplicated urinary tract infections

250 mg intravenous

every 12 hours

Bone and joint infections

2 grams intravenous

every 12 hours

Complicated urinary tract infections

500 mg intravenous

every 8 to 12 hours

Uncomplicated pneumonia; mild skin and skin-structure infections

500 mg to 1 gram intravenous

every 8 hours

Serious gynecologic and intra-abdominal infections

2 grams intravenous

every 8 hours


2 grams intravenous

every 8 hours

Very severe life-threatening infections, especially in immunocompromised patients

2 grams intravenous

every 8 hours

Lung infections caused by Pseudomonas spp. in patients with cystic fibrosis with normal renal function*

30 to 50 mg/kg intravenous to a maximum of 6 grams
per day

every 8 hours

Neonates (0 to 4 weeks)

30 mg/kg intravenous

every 12 hours

Infants and children (1 month to 12 years)

30 to 50 mg/kg intravenous to a maximum of 6 grams per day

every 8 hours


Ceftazidime for Injection is contraindicated in patients who have a history of immediate hypersensitivity reactions (e.g., anaphylaxis, serious skin reactions) to ceftazidime or the cephalosporin class of antibiotics, penicillins, or other beta-lactam antibiotics.


Immediate hypersensitivity reactions to ceftazidime have been reported. Careful inquiry should be made to determine whether the patient has had previous hypersensitivity reactions with cephalosporins or penicillins. Exercise caution if this product is to be given to penicillin-sensitive patients because cross-hypersensitivity among beta-lactam anti-bacterials has been clearly documented and may occur in up to 10% of patients with a history of penicillin allergy. If an allergic reaction to Ceftazidime for Injection occurs, discontinue the drug.

Adverse Reactions

Local Effects: reported in fewer than 2% of patients, were phlebitis and inflammation at the site of injection.

Hypersensitivity Reactions: reported in 2% of patients, were pruritus, rash, and fever. Immediate reactions, generally manifested by rash and/or pruritus, occurred in 1 in 285 patients. Toxic epidermal necrolysis, Stevens-Johnson syndrome, and erythema multiforme have also been reported with cephalosporin antibacterial drugs, including ceftazidime. Angioedema and anaphylaxis (bronchospasm and/or hypotension) have been reported very rarely.


Gastrointestinal Symptoms: reported in fewer than 2% of patients, were diarrhea (1 in 78), nausea (1 in 156), vomiting (1 in 500), and abdominal pain (1 in 416). The onset of pseudomembranous colitis symptoms may occur during or after treatment.


Central Nervous System: Reactions (fewer than 1%) included headache, dizziness, and paresthesia. Seizures have been reported with several cephalosporins, including ceftazidime. In addition, encephalopathy, coma, asterixis, neuromuscular excitability, and myoclonia have been reported in renally impaired patients treated with unadjusted dosing regimens of ceftazidime.

Less Frequent Adverse Events (fewer than 1%) were candidiasis (including oral thrush) and vaginitis.

Hematologic: Rare cases of hemolytic anemia have been reported

Pregnancy and lactation

category B

Renal and liver Impairment

Elevated levels of ceftazidime in patients with renal impairment can lead to seizures, encephalopathy, coma, asterixis, neuromuscular excitability, and myoclonus. Continued dosage should be determined by degree of renal impairment, severity of infection, and susceptibility of the causative organisms.

Laboratory Tests